PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CDK 4/6 and PI3K inhibitors: a new promise for patients with HER2‐positive breast cancer

(2021) Elisa Agostinetto et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2

(2021) Jiguang Meng et al.   BMC Pulmonary Medicine

Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets

(2021) Krzysztof Kotowski et al.   Cancers

CCNE1 and E2F1 Partially Suppress G1 Phase Arrest Caused by Spliceostatin A Treatment

(2021) Kei Kikuchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer

(2020) Huanquan Lu et al.   DEVELOPMENT GROWTH & DIFFERENTIATION

A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB

(2020) Qing-Yun Chong et al.   PHARMACOLOGICAL RESEARCH

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

(2020) Sunil Pancholi et al.   ONCOGENE

Suppression of ovarian cancer by low-intensity ultrasound through depletion of IL-6/STAT3 inflammatory pathway-maintained cancer stemness

(2020) Ting Gong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PFKFB4 is critical for the survival of acute monocytic leukemia cells

(2020) Gongai Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis

(2020) Rasmus Siersbæk et al.   CANCER CELL

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

(2020) Wenfei Ji et al.   Cell Death & Disease

CDK5 Inhibition Abrogates TNBC Stem‐Cell Property and Enhances Anti‐PD‐1 Therapy

(2020) Yuncheng Bei et al.   Advanced Science

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance

(2020) Nuray Erin et al.   DRUG RESISTANCE UPDATES

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

(2019) H. S. Rugo et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor Cell Escape from Therapy-Induced Senescence as a Model of Disease Recurrence after Dormancy

(2019) Tareq Saleh et al.   CANCER RESEARCH

Determining the protective effects of Yin-Chen-Hao Tang against acute liver injury induced by carbon tetrachloride using 16S rRNA gene sequencing and LC/MS-based metabolomics

(2019) Fang Liu et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells

(2019) Eun A Choi et al.   CANCER LETTERS

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

(2019) Mario Giuliano et al.   LANCET ONCOLOGY

A Convergence-Based Framework for Cancer Drug Resistance

(2018) David J. Konieczkowski et al.   CANCER CELL

JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance

(2018) Tianyi Wang et al.   Cell Metabolism

Hallmarks of Cellular Senescence

(2018) Alejandra Hernandez-Segura et al.   TRENDS IN CELL BIOLOGY

Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer

(2018) Subhamoy Dasgupta et al.   NATURE

Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination

(2018) Nina M. S. Gustafsson et al.   Nature Communications

c-Src regulates cargo transit via the Golgi in pancreatic acinar cells

(2018) Sergiy Kostenko et al.   Scientific Reports

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment

(2018) Jessica L.F. Teh et al.   CLINICAL CANCER RESEARCH

EMT Transition States during Tumor Progression and Metastasis

(2018) Ievgenia Pastushenko et al.   TRENDS IN CELL BIOLOGY

Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells

(2017) Hengqiang Zhao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis

(2017) Jia Zhang et al.   Nature Communications

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma

(2016) Julien Bollard et al.   GUT

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spherical Cancer Models in Tumor Biology

(2015) Louis-Bastien Weiswald et al.   NEOPLASIA

Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma

(2014) Yao-An Shen et al.   CELL CYCLE

CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis

(2014) Matilde Todaro et al.   Cell Stem Cell

Energy metabolism plasticity enables stemness programs

(2012) Clifford D.L. Folmes et al.   Annals of the New York Academy of Sciences

Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell

(2012) Toshifumi Yae et al.   Nature Communications

PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer

(2011) Seok Joong Yun et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS